



Publications gateway number: GOV-18720

Live attenuated influenza vaccine nasal spray suspension (LAIV) Patient Group Direction (PGD)

This PGD is for the supply and administration, or supply only, of live attenuated influenza vaccine (LAIV) nasal spray suspension to children and adolescents from 2 years to under 18 years of age and special educational needs (SEN) individuals aged 17 years and over and up to 25 years of age in a clinical risk group and in a SEN school in accordance with the national flu immunisation programme.

This PGD is for the supply and administration, or supply only, of LAIV by registered healthcare practitioners identified in [section 3](#), subject to any limitations to authorisation detailed in [section 2](#).

Reference no: LAIV PGD
Version no: v15.0
Valid from: 1 September 2025
Expiry date: 1 April 2026

The UK Health Security Agency (UKHSA) has developed this PGD to facilitate the delivery of publicly-funded immunisations in England in line with national recommendations.

Those using this PGD must ensure that it is organisationally authorised and signed in section 2 by an appropriate authorising person, relating to the class of person by whom the product is to be supplied, in accordance with Human Medicines Regulations 2012 (HMR2012)¹. **The PGD is not legal or valid without signed authorisation in accordance with [HMR2012 Schedule 16 Part 2](#).**

Authorising organisations must not alter, amend or add to the clinical content of this document (sections 4, 5 and 6); such action will invalidate the clinical sign-off with which it is provided. In addition, authorising organisations must not alter section 3 (Characteristics of staff).

Sections 2 and 7 can be edited within the designated editable fields provided, but only for the purposes for which these sections are provided, namely the responsibilities and governance arrangements of the NHS organisation using the PGD. The fields in section 2 and 7 cannot be used to alter, amend to or add to the clinical content. Such action will invalidate the UKHSA clinical content authorisation which is provided in accordance with the regulations

Operation of this PGD is the responsibility of commissioners and service providers. The final authorised copy of this PGD should be kept by the authorising organisation completing Section 2 for 8 years after the PGD expires if the PGD relates to adults only and for 25 years after the PGD expires if the PGD relates to children only, or adults and children. Provider organisations adopting authorised versions of this PGD should also retain copies for the periods specified above.

Individual practitioners must be authorised by name, under the current version of this PGD before working according to it.

Practitioners and organisations must check that they are using the current version of the PGD. Amendments may become necessary prior to the published expiry date. Current versions of UKHSA PGD templates for authorisation can be found from:

[Immunisation patient group direction \(PGD\) templates](#)

¹ This includes any relevant amendments to legislation.

Any concerns regarding the content of this PGD should be addressed to:

immunisation@ukhsa.gov.uk

Enquiries relating to the availability of organisationally authorised PGDs and subsequent versions of this PGD should be directed to:

For East Anglia email: england.eaimms@nhs.net

For Essex email: england.essexatimms@nhs.net

For Hertfordshire, West Essex, Bedfordshire, Luton and Milton Keynes email:

england.immsga@nhs.net


Change history

Version number	Change details	Date
v1.0 to v11v11.0	See earlier version of this PGD for change details.	1 September 2013 to 29 June 2023
v12.0	LAIV PGD amended to: • update to include the 2023 to 2024 influenza vaccination programme eligible cohorts • align the very severely immunocompromised statement to Green Book in the inclusion criteria • add children aged 2 years to less than 9 years who are household contacts of immunocompromised individuals in dose section • add additional information about use of the nasal spray in the route and administration section • update the owner of the technical memorandum from Department of Health to NHSE in the disposal section • move headache to less common adverse reaction in line with the SPC in identification of adverse reactions • add use of salicylate caution in patient advice section • add how to obtain accessible information in the written information given to patient section • updated the references	29 June 2023
v13.0	LAIV PGD amended to: • add secondary school Years 7 to 11 to criteria for inclusion section	4 July 2023
v14.0	LAIV PGD amended to: • reflect the change in LAIV vaccine from a quadrivalent to trivalent formulation, in line with recommendations from the World Health Organisation for influenza vaccine composition for use in the northern hemisphere • include information on timing of doses for the 2024 to 2025 season • confirm low ovalbumin content of Fluenz® trivalent • detail appropriate action to take when presented with individuals with unrepaired craniofacial malformations • outline updated storage data: the vaccine may only be removed from the cold chain once, for a maximum period of 12 hours at temperatures between 8°C and 25°C • remove use of oral corticosteroids in the last 14 days for asthma exacerbations as an exclusion, in line with Chapter 19 • removal of advice to reserve inactivated influenza vaccine for individuals who have not shown improvement after a further 72 hours following an initial 72 hour period of active wheeze, increased bronchodilator use, or both • include minor rewording, layout and formatting changes for consistency with other UKHSA PGDs	9 July 2024

v15.0	LAIV PGD amended to: • include a new cohort; special educational needs (SEN) individuals aged 17years and over and up to 25 years of age in a clinical risk group and in a SEN school • update off-label administration of LAIV to SEN individuals • update dose and frequency of administration section in relation to SEN individuals • update the formulation of the vaccine • update egg-free cell-based terminology to cell-cultured inactivated vaccine (IIVc) and delete quadrivalent as the vaccines for 2025 to 2026 programme are trivalent • clarify quantity supplied and route and administration sections with regard to supply, administration and over-labelling • clarify the additional requirements with regard to healthcare support workers • include minor rewording, layout and formatting changes for consistency with other UKHSA PGDs • update references	25 June 2025
-------	--	--------------

1. PGD development

This PGD has been developed by the following health professionals on behalf of the UKHSA:

Developed by:	Name	Signature	Date
Pharmacist (Lead Author)	Suki Hunjunt Lead Pharmacist Immunisation Programmes, UKHSA		1 July 2025
Doctor	Jamie Lopez-Bernal Consultant Epidemiologist Chief Medical Advisor, UKHSA		1 July 2025
Registered Nurse (Chair of Expert Panel)	Greta Hayward Consultant Midwife for Immunisation Programmes, UKHSA		1 July 2025

This PGD has been peer reviewed by the UKHSA Immunisations PGD Expert Panel in accordance with the UKHSA PGD and Protocol Policy. It has been ratified by the UKHSA Medicines Governance Committee.

Expert Panel

Nicholas Aigbogun	Consultant in Communicable Disease Control, Yorkshire and Humber Health Protection Team, UKHSA
Jessica Baldasera	Health Protection Practitioner, North East Health Protection Team Regions Directorate, UKHSA
Helen Beynon	Clinical Advisor, Immunisation Clinical Advice Response Service (CARS), NHS England London
Alison Campbell	Screening and Immunisation Coordinator, Public Health Commissioning NHS England (NHS England) Midlands
Naveen Dosanjh	Senior Clinical Advisor – Vaccinations, NHS England
Helen Eley	Lead Immunisation Nurse Specialist, Immunisation Programmes, UKHSA
Jane Freeguard	Deputy Director of Vaccination – Medicines and Pharmacy NHS England
Rosie Furner	Advanced Specialist Pharmacist - Medicines Governance, Specialist Pharmacist Services (SPS)
Ed Gardner	Advanced Paramedic Practitioner/Emergency Care Practitioner, Medicines Manager, Proactive Care Lead
Shilan Ghafoor	Medicines Governance Lead Pharmacist, UKHSA
Elizabeth Lockett	Senior Screening and Immunisation Manager, Screening and Immunisation Team – Kent and Medway, NHS England South East
Briony Mason	Vaccination Manager, Professional Midwifery Advocate, Vaccination and Screening, NHS England, West Midlands
Vanessa MacGregor	Consultant in Communicable Disease Control, East Midlands Health Protection Team, UKHSA
Tushar Shah	Lead Pharmacy Adviser, NHS England London

2. Organisational authorisations


The PGD is not legally valid until it has had the relevant organisational authorisation.

It is the responsibility of the organisation that has legal authority to authorise the PGD, to ensure that all legal and governance requirements are met. The authorising body accepts governance responsibility for the appropriate use of the PGD.

NHS England East of England authorises this PGD for use by the services or providers listed below:

Authorised for use by the following organisations and/or services	
NHS England East of England commissioned immunisation services or NHS Trust providing immunisation services covering Norfolk, Suffolk, Cambridgeshire, Peterborough, Essex, Southend-on-Sea, Thurrock, Bedfordshire, Hertfordshire, Luton and Milton Keynes local authorities, and Health and Justice facilities where NHS England East of England is the commissioner.	
Limitations to authorisation	
None	

Organisational approval (legal requirement)			
Role	Name	Sign	Date
Medical Director	Dr Ian Gibson		07/07/2025

Additional signatories according to locally agreed policy			
Role	Name	Sign	Date
Screening and Immunisation Lead	Dr Eleanor Powers		02/07/2025
Pharmacist	Sarah Cavanagh		02/07/2025
Screening and Immunisation Coordinator	Lucy Blatch		02/07/2025

Local enquiries regarding the use of this PGD may be directed to

For East Anglia email: england.eaimms@nhs.net

LAIV PGD v15.0 Valid from: 1 September 2025 Expiry: 1 April 2026

Page 6 of 21

For Essex email: england.essexatimms@nhs.net

For Hertfordshire, West Essex, Bedfordshire, Luton and Milton Keynes email:
england.immsqa@nhs.net

For the Health Protection Team email: EastofEnglandhpt@ukhsa.gov.uk

[Section 7](#) provides a practitioner authorisation sheet. Individual practitioners must be authorised by name to work to this PGD. Alternative practitioner authorisation sheets may be used where appropriate in accordance with local policy but this should be an individual agreement or a multiple practitioner authorisation sheet as included at the end of this PGD.

3. Characteristics of staff

Qualifications and professional registration	All practitioners should only administer vaccination where it is within their clinical scope of practice to do so. Practitioners must also fulfil the additional requirements and continued training requirements to ensure their competency is up to date, as outlined in the section below. Registered professional with one of the following bodies: • nurses and midwives currently registered with the Nursing and Midwifery Council (NMC) • pharmacists and pharmacy technicians currently registered with the General Pharmaceutical Council (GPhC) (Note: This PGD is not relevant to the national community pharmacy seasonal influenza vaccination advanced service nor to the privately provided community pharmacy services). • chiropodists/podiatrists, dieticians, occupational therapists, orthoptists, orthotists/prosthetists, paramedics, physiotherapists, radiographers and speech and language therapists currently registered with the Health and Care Professions Council (HCPC) • dental hygienists and dental therapists registered with the General Dental Council • optometrists registered with the General Optical Council Practitioners must also fulfil all the Additional requirements. Check Section 2 (Limitations to authorisation) to confirm whether all the registered practitioners listed above have organisational authorisation to work under this PGD.
Additional requirements	Additionally, practitioners: • must be authorised by name as an approved practitioner under the current terms of this PGD before working to it • must have undertaken appropriate training for working under PGDs for supply/administration of medicines • must be competent in the use of PGDs (see NICE Competency framework for health professionals using PGDs) • must be familiar with the vaccine product and alert to changes in the Summary of Product Characteristics (SPC), Immunisation Against Infectious Disease (the Green Book) and national and local immunisation programmes • must have undertaken training appropriate to this PGD as required by local policy and in line with the National Minimum Standards and Core Curriculum for Immunisation Training • must be competent to undertake immunisation and to discuss issues related to immunisation • must be competent in the handling and storage of vaccines and management of the cold chain • must be competent in the recognition and management of anaphylaxis • must have access to the PGD and associated online resources • should fulfil any additional requirements defined by local policy • must be satisfied that where the Health Care Support Worker (HCSW) is administering the LAIV vaccine that the HCSW has the experience, knowledge and skills to provide the care as per the UKHSA National Minimum Standards and Core Curriculum for Vaccination. It should be noted that the individual administering the vaccine is accountable for their practice in accordance with their individual contract of employment • The individual practitioner must be authorised by name, under the current version of this PGD before working according to it.

Continued training requirements	Practitioners must ensure they are up to date with relevant issues and clinical skills relating to immunisation and management of anaphylaxis, with evidence of appropriate Continued Professional Development (CPD). Practitioners should be constantly alert to any subsequent recommendations from the UKHSA, NHS England and other sources of medicines information. Note: The most current national recommendations should be followed but a Patient Specific Direction (PSD) or a prescription may be required to administer the vaccine in line with updated recommendations that are outside the criteria specified in this PGD.
--	---

4. Clinical condition or situation to which this PGD applies

Clinical condition or situation to which this PGD applies	LAIV is indicated for the active immunisation of children and adolescents from 2 years to under 18 years of age and individuals 17 years to 25 years who are in a clinical risk group and in a Special Educational Needs (SEN) school for the prevention of influenza infection, in line with the recommendations given in Chapter 19 of Immunisation Against Infectious Disease: the Green Book, annual flu letter(s) and subsequent correspondence and publications from UKHSA and NHS England.
Criteria for inclusion	For the 2025 to 2026 influenza season, LAIV should be offered in accordance with national recommendations to the following groups: From 1 September 2025: • all those aged 2 or 3 years on 31 August 2025 (with a date of birth on or after 1 September 2021 and on or before 31 August 2023) • all primary school-aged children in Reception to Year 6 (aged 4 to 10 years old on 31 August 2025) including home-schooled and other children not in mainstream education • secondary school-aged children in Years 7 to 11 including home-schooled and other children not in mainstream education Note: some school aged children might be outside of the age ranges outlined in the above paragraphs (for example, if a child has been accelerated or held back a year). It is acceptable to offer and deliver influenza immunisation to these children with their class peers under this PGD • children and adolescents from 2 years to under 18 years of age who are in a clinical risk group category listed in Chapter 19 of the Green Book such as: ○ chronic (long-term) respiratory disease, such as asthma (that requires continuous or repeated use of inhaled or systemic steroids or with previous exacerbations requiring hospital admission, but see also criteria for exclusion below), bronchitis or cystic fibrosis ○ chronic heart disease and vascular disease ○ chronic kidney disease at stage 3, 4 or 5 ○ chronic liver disease ○ chronic neurological disease, such as cerebral palsy or motor neurone disease, ○ learning disability diabetes and adrenal insufficiency ○ asplenia or dysfunction of the spleen ○ a weakened immune system due to disease (such as HIV/AIDS) or treatment (such as cancer treatment) ○ morbidly obese individuals (aged from 16 years) with a BMI $\geq 40\text{kg/m}^2$ and above • individuals aged 17 years and up to 25 years of age attending a special educational needs (SEN) school and are in a clinical risk group (see Chapter 19) • children and adolescents from 2 years to under 18 years of age who are close household contacts of immunocompromised individuals. This would also include individuals who expect to share living accommodation on most days over the winter with immunocompromised individuals and therefore for whom continuing close contact is unavoidable. This may include carers. Note: close contacts (example household members or carers) of very severely immunocompromised individuals, for example bone marrow transplant individuals requiring isolation, should receive inactivated influenza vaccine and not LAIV, see the inactivated influenza PGD. • individuals, from 16 years to under 18 years of age, who are in receipt of a carer's allowance, or those who are the main carer of an older or disabled person whose welfare may be at risk if the carer falls ill

continued over page

Criteria for inclusion (continued)	• frontline staff from 16 years to under 18 years of age without employer-led occupational health schemes employed: ○ by a registered residential care or nursing home or registered domiciliary care provider, who are directly involved in the care of vulnerable individuals who are at increased risk from exposure to influenza ○ by a voluntary managed hospice provider, who are directly involved in the care of vulnerable individuals who are at increased risk from exposure to influenza ○ through Direct Payments (personal budgets) or Personal Health Budgets, such as Personal Assistants, to deliver domiciliary care to individuals ○ to deliver social care services and are in direct contact with those who are clinically vulnerable to flu, who receive care and support services from the social care provider
Criteria for exclusion²	Individuals for whom no valid consent has been received (or for whom a best-interests decision in accordance with the Mental Capacity Act 2005, has not been obtained). For further information on consent, see Chapter 2 of the Green Book. Several resources are available to inform consent (see written information to be given to individual, parent or carer section). LAIV must not be given under this PGD to: • children and infants under 2 years of age • adults aged 18 years and over except those individuals who are attending SEN school and are in a clinical risk group (see Criteria for inclusion) • individuals who have received a dose of influenza vaccine for the current season, unless they are individuals aged 2 to less than 9 years in a clinical risk group category listed in Chapter 19 of the Green Book who should, in the first season they are vaccinated against influenza, receive a second dose of LAIV at least 4 weeks after the first dose • individuals with a confirmed anaphylactic reaction to a previous dose of influenza vaccine • individuals with a confirmed anaphylactic reaction to any component of LAIV (such as gelatine) or residue from the manufacturing process (such as gentamicin), with the exception of egg proteins (see Action to be taken if the individual is excluded section) • individuals with severe anaphylaxis to egg which has previously required intensive care • individuals with egg allergy (less severe than anaphylaxis requiring intensive care) but who also have another condition which contraindicates LAIV • individuals with severe asthma who have previously required intensive care for asthma exacerbation or who require regular oral steroids for the maintenance of asthma control, unless LAIV is advised by their respiratory specialist • individuals receiving salicylate therapy (other than topical treatment for localised conditions) because of the association of Reye's syndrome with salicylates and wild-type influenza infection • individuals with unrepaired craniofacial malformations • pregnant individuals (see the UKHSA Inactivated influenza PGD) Note: There is no need to specifically test eligible girls for pregnancy or to advise avoidance of pregnancy in those who have been recently vaccinated • individuals offered vaccination as part of an employer's occupational health scheme

continued over page

² Exclusion under this PGD does not necessarily mean the medication is contraindicated, but it would be outside its remit and another form of authorisation will be required.

Criteria for exclusion (continued)	Refer to the UKHSA Inactivated influenza PGD for the following groups of excluded individuals: • individuals who are clinically severely immunodeficient due to a condition or immunosuppressive therapy such as: ○ acute and chronic leukaemias ○ lymphoma ○ HIV, which is not suppressed by antiretroviral therapy ○ cellular immune deficiencies ○ high dose corticosteroids (prednisolone at least 2mg/kg/day for a week or 1mg/kg/day for a month or equivalent) • individuals for whom close contact with very severely immunocompromised individuals (for instance, bone marrow transplant individuals requiring isolation) is likely or unavoidable (for example, household members) Temporary exclusions LAIV administration should be postponed for individuals who: • are suffering from acute febrile illness until completely recovered • are suffering from heavy nasal congestion which may impede delivery of the vaccine to the nasopharyngeal mucosa until congestion has resolved • have a history of active wheezing in the past 72 hours or those who have increased their use of bronchodilators in the previous 72 hours. See action to be taken if the individual is excluded • received treatment with influenza antiviral agents in the last 48 hours, until 48 hours following the cessation of treatment with influenza antiviral agents
Cautions including any relevant action to be taken	Facilities for management of anaphylaxis should be available at all vaccination sites (see Chapter 8 of the Green Book) and advice issued by the Resuscitation Council UK. Individuals who have immunosuppression or who are living with HIV may not make a full antibody response to the vaccine.
Action to be taken if the individual is excluded continued over page	Children and adolescents who are eligible for influenza vaccination but for whom LAIV is contraindicated or is otherwise unsuitable, for instance due to the route or non-acceptance of porcine gelatine content, should be considered for an appropriate alternative inactivated influenza vaccine (see the UKHSA Inactivated influenza PGD). Children and adolescents with a history of severe anaphylaxis to egg which has required intensive care should ideally be referred to specialists for potential LAIV immunisation in hospital. LAIV remains the preferred vaccine for this group and the intranasal route is less likely to cause systemic reactions. Egg-allergic individuals can alternatively be given the cell-cultured inactivated vaccine (IIVc), see the UKHSA Inactivated influenza PGD. The Joint Committee on Vaccination and Immunisation (JCVI) has advised that, except for those with severe anaphylaxis to egg which has previously required intensive care, children with an egg allergy can be safely vaccinated with LAIV in any setting (including primary care and schools). Fluenz[®] contains less than 0.024 micrograms ovalbumin per dose, equivalent to less than 0.12 micrograms per ml and is classed as having a very low ovalbumin content. Individuals who have previously required intensive care for asthma exacerbation or who require regular oral steroids for the maintenance of asthma control should only be given LAIV on the advice of their specialist. As these children are a defined risk group for influenza, those who cannot receive LAIV should receive an inactivated influenza vaccine (see the UKHSA Inactivated influenza PGD). No data exist in reference to the safety of intranasal administration of Fluenz[®] in individuals with unrepaired craniofacial malformations. In such cases, LAIV may be

Action to be taken if the individual is excluded (continued)	considered unsuitable and therefore the inactivated influenza vaccine should be offered instead (see the UKHSA Inactivated influenza PGD). All pregnant individuals should be offered inactivated influenza vaccine unless otherwise contraindicated (see the UKHSA Inactivated influenza PGD). Vaccination with inactivated influenza vaccine should be considered for immunosuppressed individuals excluded from receiving LAIV and those who are contacts of individuals who are very severely immunocompromised (see the UKHSA Inactivated Influenza PGD). Individuals temporarily excluded may be offered LAIV at a later date. In case of postponement, arrange a future date for vaccination. Individuals suffering from heavy nasal congestion could be given an intramuscular influenza vaccine instead. Individuals who have a history of active wheezing in the past 72 hours, or those who have increased their use of bronchodilators in the previous 72 hours, should be offered an inactivated influenza vaccine to avoid delaying protection in this high-risk group (see the UKHSA Inactivated influenza PGD). Seek appropriate advice from the local Screening and Immunisation Team, local Health Protection Team or individual's clinician as required. The risk to the individual of not being immunised must be taken into account. Document the reason for exclusion and any action taken in the individual's clinical records. Inform or refer to the individual's GP or a prescriber as appropriate.
Action to be taken if the individual, parent or carer declines treatment	Informed consent, from the individual or a person legally able to act on the individual's behalf, must be obtained for each administration and recorded appropriately. For further information on consent, see Chapter 2 of the Green Book. Advise the individual, parent or carer about the protective effects of the vaccine, the risks of infection and potential complications. If the individual, parent or carer of an eligible child refuses LAIV because of its porcine gelatine content (and they understand that it is the most effective product in the programme), advise the individual, parent or carer they can request an alternative injectable vaccine. UKHSA has procured IIVc for these children. Refer to the UKHSA Inactivated Influenza Vaccine PGD. Document the advice given and decision reached. Inform or refer to the GP or prescriber as appropriate.
Arrangements for referral for medical advice	As per local policy

5. Description of treatment

Name, strength and formulation of drug	Live attenuated influenza vaccine nasal spray suspension (0.2ml): Fluenz® in pre-filled single-use nasal applicator 0.2ml dose contains: A/ Victoria/4897/2022 (H1N1)pdm09 - like strain (A/ Norway/31694/2022, MEDI 369815) $10^{7.0 \pm 0.5}$ FFU*** A/Thailand/8/2022 (H3N2) - like strain (A/Thailand/8/2022, MEDI 370626) $10^{7.0 \pm 0.5}$ FFU*** B/ Austria/1359417/2021 - like strain (B/ Austria/1359417/2021, MEDI 355292) $10^{7.0 \pm 0.5}$ FFU*** The vaccine may contain residues of the following substances: egg proteins (e.g. ovalbumin) and gentamicin. The maximum amount of ovalbumin is less than 0.024 micrograms per 0.2 ml dose (0.12 micrograms per ml).
Legal category	Prescription only medicine (POM)
Black triangle▼	No
Off-label use	The SPC states children who have not previously been vaccinated against seasonal influenza should be given a second dose after an interval of at least 4 weeks. However, JCVI has advised that children who are not in a clinical risk group, only require a single dose of LAIV irrespective of whether they have received influenza vaccine previously. Fluenz® is contraindicated in children and adolescents receiving salicylate therapy because of the association of Reye's syndrome with salicylates and wild-type influenza infection. However, LAIV may be administered off-label to individuals receiving topical salicylate treatment for the management of localised conditions, in accordance with Chapter 19 of the Green Book. JCVI has advised that, except for those with severe anaphylaxis to egg which has previously required intensive care, children with an egg allergy can be safely vaccinated with LAIV in any setting (including primary care and schools). Fluenz® is contraindicated in children and adolescents with severe asthma, however, JCVI have advised children with asthma on inhaled corticosteroids may safely be given LAIV, irrespective of the dose prescribed. Fluenz® is not licensed for use in individuals aged 18 years and over. However, LAIV may be given to individuals aged 18 years and over who attend a SEN school and are in a clinical risk group in accordance with the recommendations in Chapter 19 and by JCVI. Vaccines should be stored according to the conditions detailed in the storage section below. However, in the event of an inadvertent or unavoidable deviation of these conditions, refer to Vaccine Incident Guidance. Where vaccines are assessed in accordance with these guidelines as appropriate for continued use, this would constitute off-label administration under this PGD. Where a vaccine is recommended off-label consider, as part of the consent process, informing the individual, parent or carer that the vaccine is being offered outside of product licence but in accordance with national guidance.

Route and method of administration

Only specified registered healthcare professionals can work under a PGD, therefore HCSWs cannot work under a PGD. If the PGD is used for “supply only”, subsequent self-administration or administration by another person, such as a carer or healthcare worker is outside the remit of this PGD and should only take place in well-defined local circumstances covered by training and local operating protocols and within the same vaccination session.

Administration under this PGD must be directly by the registered health professional named in [section 7](#).

Administration under this PGD must be directly by the registered health professional named in [section 7](#). LAIV is for **intranasal application** only.

Do not use with a needle. Do not inject.

Single dose of 0.2ml of LAIV, administered as 0.1ml in each nostril.

Do not use Fluenz® if the expiry date has passed or the sprayer appears damaged, for example, if the plunger is loose or displaced from the sprayer or if there are any signs of leakage.

Check the appearance of the vaccine before administration. The suspension should be colourless to pale yellow, clear to opalescent. Small white particles may be present. In instances where there is variation of expected appearance of the vaccine prior to preparation and administration, discard the vaccine in accordance with local procedures.


The individual can breathe normally during vaccine administration and there is no need to actively inhale or sniff.

Administration does not need to be repeated if the individual sneezes or blows their nose immediately following administration.

Check product name, batch number and expiry date before administration.

The [SPC](#) provides further guidance on administration.

Instructions for administration



Remove the rubber tip protector. Do not remove the dose-divider clip at the other end.

With the patient upright, position the tip just inside the nostril and in a single motion, depress the plunger as rapidly as possible until the dose-divider clip prevents movement.

For administration into the other nostril, pinch and remove the dose-divider clip from the plunger.

Place the tip just inside the other nostril. In a single motion, depress the plunger as rapidly as possible to deliver the remaining vaccine.

Dose and frequency of administration	Single dose of 0.2ml of LAIV, administered as 0.1ml in each nostril. Children in clinical risk groups Children aged 2 years to less than 9 years who are in a clinical risk group category listed in Chapter 19 of the Green Book and who have not received influenza vaccine before, should receive a second dose of LAIV at least 4 weeks after the first dose. Children aged 2 years to less than 9 years who are household contacts of immunocompromised individuals should be vaccinated in accordance with the advice on children in clinical risk groups (see Chapter 19). Individuals over 17 years of age and up to 25 years of age who are in a clinical risk group and in a SEN school can be vaccinated with their peers. Second dose: 0.2ml of LAIV, administered as 0.1ml in each nostril. If LAIV is unavailable for second doses, for example due to batch expiry, then offer an age-appropriate and available inactivated influenza vaccine (see UKHSA Inactivated influenza PGD)
Duration of treatment	As outlined in dose and frequency of administration above.
Quantity to be supplied or administered	0.2ml dose to be administered as 0.1ml in each nostril, or 0.2ml of LAIV to be supplied to the individual for immediate self-administration or administration by another person, such as a carer or healthcare worker within the same setting. Where a vaccine is supplied for individual self-administration or administration by a carer or healthcare worker, the vaccine must be administered prior to the individual leaving the immunisation session (see Route and method section). A single dose of LAIV supplied by a healthcare professional under this PGD for immediate self-administration or administration by another person, such as a carer or healthcare worker, in the same vaccination session, does not require over-labelling. Note: The act of administration by anyone other than the registered professional named in section 7 is outside the remit of this PGD and should only take place in well-defined local circumstances covered by training and local operating protocols. Children aged 2 years to less than 9 years old in a clinical risk category and receiving influenza immunisation for the first time: this dose (0.2ml) should be repeated after a minimum of 4 week interval.
Supplies	LAIV has been purchased centrally for children. These vaccines should be ordered as per the usual mechanisms for the routine childhood immunisation programme. LAIV for children can be ordered through the ImmForm website. Protocols for the ordering, storage and handling of vaccines should be followed to prevent vaccine wastage (see the Green Book Chapter 3).
Storage	Store at +2°C to +8°C. Store in original packaging in order to protect from light. Do not freeze. Before use, the vaccine may be removed from the cold chain once, for a maximum period of 12 hours at a temperature not above 25°C. Data indicates the vaccine components are stable for 12 hours at temperatures between 8°C and 25°C. If the vaccine has not been used within this 12 hour period, it should be immediately discarded, in line with local clinical waste procedures. In the event of an inadvertent or unavoidable deviation of these conditions, vaccines that have been stored outside the conditions stated above should be quarantined

Storage (continued)	and risk assessed on a case-by-case basis for suitability of continued off-label use or appropriate disposal. Refer to Vaccine Incident Guidance .
Disposal	Follow local clinical waste policy and NHS standard operating procedures to ensure safe and secure waste disposal. Equipment used for immunisation, including discharged or partially discharged vaccines in an applicator, should be disposed of safely, as medicinally-contaminated clinical waste for incineration, in a UN-approved waste receptacle (usually a sharps box), according to waste disposal arrangements and NHS England guidance (HTM 07-01: safe and sustainable management of healthcare waste).
Drug interactions	There is a potential for influenza antiviral agents to lower the effectiveness of the LAIV. Therefore, influenza antiviral agents and LAIV should not be administered concomitantly. LAIV should be delayed until 48 hours following the cessation of treatment with influenza antiviral agents. Administration of influenza antiviral agents within the 2 weeks following administration of LAIV may affect the response to the vaccine. Do not administer LAIV to those receiving salicylate therapy (other than topical treatment for localised conditions) and do not use salicylates for 4 weeks after vaccination. LAIV can be given at the same time as other vaccines (both live and inactivated). Live vaccines which replicate in the mucosa, such as live attenuated influenza vaccine (LAIV) are unlikely to be seriously affected by concomitant COVID-19 vaccination. It is generally better for vaccination to proceed to avoid any further delay in protection and to avoid the risk of the individual not returning for a later appointment (see Chapter 19). A detailed list of drug interactions is available from the vaccine's SPC.
Identification and management of adverse reactions	Very common adverse reactions observed after administration of LAIV are decreased appetite, nasal congestion, rhinorrhoea and malaise. Commonly encountered reactions include myalgia, headache and pyrexia. The incidence of hypersensitivity reactions (including urticaria and facial oedema), rash and epistaxis are considered to be uncommon. A detailed list of adverse reactions is available from the vaccine's SPC.
Reporting procedure of adverse reactions	Healthcare professionals and individuals, parents or carers are encouraged to report suspected adverse reactions to the Medicines and Healthcare products Regulatory Agency (MHRA) using the Yellow Card reporting scheme or search for MHRA Yellow Card in the Google Play or Apple App Store. Any adverse reaction to the vaccine should be documented in the individual's record and the individual's GP should be informed.
Written information to be given to individual or carer	Offer the marketing authorisation holder's patient information leaflet (PIL) provided with the vaccine. For resources in accessible formats and alternative languages, please visit Home - Health Publications. Where applicable, inform the individual/parent/carer that the PIL with large print, Braille or audio CD can be ordered from the manufacturer (see electronic medicines compendium). When LAIV is administered, there is no legal requirement to provide the manufacturer's PIL to the individual at the time of administration, although this may be considered good practice.

continued over page

Special considerations and additional information (continued)	LAIV should be offered to eligible children aged from 2 years to less than 18 years of age. Where parents object to LAIV on the grounds of its porcine gelatine content or where LAIV is unsuitable, children should be offered the injectable cell-cultured influenza vaccine (IIVc), see the UKHSA Inactivated influenza PGD. If the PGD is used for supply only for subsequent administration by an appropriately trained HCSW, the registered practitioner named in section 7 of this PGD must supply the vaccine to the individual or carer. The HCSW cannot supply the medicine. Children with cochlear implants can be given LAIV safely although ideally not in the week prior to implant surgery or for 2 weeks afterwards, or if there is evidence of ongoing cerebrospinal fluid leak. Exposure of healthcare professionals Very severely immunosuppressed individuals should not administer LAIV. Other healthcare workers who have less severe immunosuppression or are pregnant, should follow normal clinical practice to avoid inhaling the vaccine and ensure that they themselves are appropriately vaccinated.
Records	The practitioner must ensure the following is recorded: • that valid informed consent was given or a decision to vaccinate was made in the individual's best interests in accordance with the Mental Capacity Act 2005 • name of individual, address, date of birth and GP with whom the individual is registered (or record where an individual is not registered with a GP and that appropriate advice has been given) • name of immuniser • name and brand of vaccine • date of administration or supply • dose, form and route of administration of vaccine • quantity administered or supplied • batch number and expiry date • advice given, including advice given if the individual is excluded or immunisation is declined • details of any adverse drug reactions and actions taken • whether supplied only or supplied and administered via PGD Records should be signed and dated (or password-controlled on e-records). All records should be clear, legible and contemporaneous. It is important that vaccinations given either at a general practice or elsewhere (for example, at schools) are recorded on appropriate health records for the individual (using the appropriate clinical code). If given elsewhere, a record of vaccination should be returned to the individual's general practice to ensure a complete health record is held by the GP, allow clinical follow up and to avoid duplicate vaccination. A record of all individuals receiving treatment under this PGD should also be kept for audit purposes in accordance with local policy.

6. Key references

Key references	LAIV • Immunisation Against Infectious Disease: the Green Book. Chapter 19 and Chapter 2, Green Book, Immunisation against infectious diseases • Summary of Product Characteristics: Fluenz® trivalent nasal spray suspension 6 June 2025 www.medicines.org.uk/emc/product/15790/smpc • Collection: Annual Flu Programme www.gov.uk/government/collections/annual-flu-programme • The national flu immunisation programme 2025 to 2026 letter, published 13 February 2025 www.gov.uk/government/publications/national-flu-immunisation-programme-plan-2025-to-2026/national-flu-immunisation-programme-2025-to-2026-letter • Influenza vaccine written instruction templates for adoption. NHS Specialist Pharmacy Service www.sps.nhs.uk/articles/influenza-vaccine-written-instruction-templates-for-adoption/ • Flu immunisation training recommendations, updated 9 August 2024 www.gov.uk/government/publications/flu-immunisation-training-recommendations • Flu Vaccinations: Supporting people with learning disabilities, updated 25 September 2018 www.gov.uk/government/publications/flu-vaccinations-for-people-with-learning-disabilities • Extension of the Influenza programme to children in England Extension of the Influenza immunisation programme to children in England • Workforce planning and models of delivery toolkit Workforce planning and models of delivery toolkit-Extension of the national flu immunisation programme to children General • NHS England Health Technical Memorandum 07-01: safe and sustainable management of healthcare waste www.england.nhs.uk/publication/management-and-disposal-of-healthcare-waste-hm-07-01/ • Immunisation Against Infectious Disease: The Green Book. Chapter 2 https://www.gov.uk/government/publications/consent-the-green-book-chapter-2 • National Minimum Standards and Core Curriculum for Immunisation Training, updated 23 June 2025 www.gov.uk/government/publications/national-minimum-standards-and-core-curriculum-for-immunisation-training-for-registered-healthcare-practitioners • NICE Medicines Practice Guideline 2 (MPG2): Patient Group Directions, updated 27 March 2017 https://www.nice.org.uk/guidance/mpg2 • NICE MPG2 Patient group directions: competency framework for health professionals using patient group directions, updated 4 January 2018 https://www.nice.org.uk/guidance/mpg2/resources • UKHSA Immunisation Collection. www.gov.uk/government/collections/immunisation • Vaccine Incident Guidance www.gov.uk/government/publications/vaccine-incident-guidance-responding-to-vaccine-errors
----------------	--

7. Practitioner authorisation sheet

LAIV PGD v15.0 Valid from: 1 September 2025 Expiry: 1 April 2026

Before signing this PGD, check that the document has had the necessary authorisations in section 2. Without these, this PGD is not lawfully valid.

Practitioner

By signing this PGD you are indicating that you agree to its contents and that you will work within it.

PGDs do not remove inherent professional obligations or accountability.

It is the responsibility of each professional to practise only within the bounds of their own competence and professional code of conduct.

I confirm that I have read and understood the content of this PGD and that I am willing and competent to work to it within my professional code of conduct.			
Name	Designation	Signature	Date

Authorising manager

I confirm that the practitioners named above have declared themselves suitably trained and competent to work under this PGD. I give authorisation on behalf of for the above named health care professionals who have signed the PGD to work under it.			
Name	Designation	Signature	Date

Note to authorising manager

Score through unused rows in the list of practitioners to prevent practitioner additions post managerial authorisation.

This authorisation sheet should be retained to serve as a record of those practitioners authorised to work under this PGD.